Cullinan Therapeutics (CGEM) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Cullinan Therapeutics (CGEM) had its price target raised by Wedbush from $34.00 to $36.00. They now have an "outperform" rating on the stock.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics (NASDAQ:CGEM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.